Popular search terms:
Developments in cell-based vaccine technology
CSL spotlights developments in cell-based vaccine technology at Australian Research a…
2019 Centenary Fellowship Winners Announced
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL …
CSL Donates to Indonesian Relief Operations
CSL today announced an AUD$50,000 donation in support of Indonesian earthquake and ts…
CSL a Top 100 Company for Diversity & Inclusion
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global D…
Centenary Fellowship Applications Open
$2.5 Million Funding Available to Australian Biomedical Researchers
CSL Lifts Profit Guidance
CSL Limited today announced a revised profit outlook for fiscal 2018.
We are passionate about people
Mike Deem
Senior Vice President and General Manager, CSL Plasma
When Mike Deem joined CSL nearly 30 years ago, he was a college student in search of tuition reimbursement. That college job turned into an exciting career. He's now SVP and General Manager of CSL Plasma and credits his success to the mentors and development opportunities provided by the company.
